ArticleJournal of clinical practice and research2025
Primary Breast Myeloid Sarcoma Mimicking Breast Carcinoma: A Case Report.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloid sarcoma (MS) is a rare extramedullary tumor composed of immature myeloid cells, most commonly associated with acute myeloid leukemia (AML). Although it typically occurs in the skin, lymph nodes, bone, and soft tissue, breast involvement is extremely uncommon and may mimic breast carcinoma or lymphoma. Case Report: A 34-year-old woman presented with a left breast mass initially suspected to be carcinoma. Histopathological and immunohistochemical analyses confirmed myeloid sarcoma, with no evidence of systemic involvement. The patient achieved complete remission after AML-based induction chemotherapy followed by allogeneic stem cell transplantation and remains in remission at one year of follow-up. Conclusion: Breast MS is a rare and diagnostically challenging entity. Accurate immunohistochemical evaluation is crucial to avoid misdiagnosis and treatment delay. AML-oriented systemic chemotherapy, and allogeneic stem cell transplantation when appropriate, remain the most effective strategies to achieve long-term remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.